Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that 73% of endocrinologists and nearly 60% of primary care physicians say they are likely to prescribe Sanofi-Aventis's Acomplia (rimonabant) to treat patients with obesity, following the drug's anticipated launch in mid 2006.

A new PhysicianForum primary market research report entitled Obesity: New Treatments and Reimbursement Issues finds that, while Acomplia has the potential to reach blockbuster status, nearly half of the managed care pharmacy directors surveyed indicate that the drug will likely not be covered in their product formularies owing to general policies that exclude weight- loss treatments from prescription benefits.

"If approved, Acomplia will be the first novel drug to hit the obesity market over the past five years, and many doctors say they will prescribe this drug for the indication," said Donny Wong, Ph.D., analyst at Decision Resources, Inc. "However, a significant barrier to the use of Acomplia will be the attitudes and policies of HMO pharmacy directors, who continue to view obesity as a lifestyle issue rather than as a true medical condition."

Obesity: New Treatments and Reimbursement Issues is based on a U.S. survey of 20 HMO pharmacy and medical directors, 70 endocrinologists, and 72 primary care physicians. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a primary research service from Decision Resources that offers access to high-volume-prescribing PCPs, specialists, and managed care organization representatives in the United States. PhysicianForum offers analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Oral Chemotherapy Will Play a Larger Role in Cancer Treatment

View Now